Skip to main content
Erschienen in: Drugs in R&D 2/2004

01.03.2004 | Original Research Article

Improvement of Cutaneous Microcirculation and Oxygen Supply in Patients with Chronic Venous Insufficiency by Orally Administered Extract of Red Vine Leaves AS 195

A Randomised, Double-Blind, Placebo-Controlled, Crossover Study

verfasst von: Ulrich Kalus, Juergen Koscielny, Alexandre Grigorov, Eckhard Schaefer, Hubertus Peil, Holger Kiesewetter

Erschienen in: Drugs in R&D | Ausgabe 2/2004

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the effect of the red vine leaf extract AS 195 on cutaneous microvascular blood flow, transcutaneous oxygen pressure (tcpO2), and leg oedema in patients with chronic venous insufficiency (CVI).

Design and patients

The study was a randomised, double-blind, placebo-controlled, crossover trial for which 129 men and women, aged ≥18 years, with CVI stage I or II were screened. Seventy-one fulfilled the inclusion criteria and were randomised.

Interventions

A total of 71 patients were divided into two groups. The first group (n=36) received AS 195 360mg once daily during a first 6-week treatment period, followed by a 4-week placebo washout period and then placebo during the second 6-week treatment period. The second group (n=35) started with placebo and received AS 195 360mg after the placebo washout. The cutaneous microvascular blood flow in the malleolar region was measured using a newly developed laser Doppler device. TcpO2 was measured using a solid-state electrode.

Results

After 6 weeks, patients in the AS 195 group had increased microvascular blood flow values (+241.8±18.7 arbitrary units [AU] versus a decrease of −41.0±18.7AU in the placebo group; p < 0.0001). Oxygen increased to 1.35±0.97mm Hg (placebo: decrease of −7.27±0.97mm Hg; p < 0.0001). After 6 weeks of treatment the leg circumference was decreased (ankle level: by −0.39±0.09cm versus +0.29±0.09cm; p < 0.0001; calf level: by −0.54±0.05cm versus +0.14±0.05cm; p < 0.0001).

Conclusion

The administration of AS 195 improved objective symptoms of CVI and may prevent CVI deterioration.
Fußnoten
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literatur
1.
Zurück zum Zitat Van den Oever R, Hepp B, Debbaut B, et al. Socio-economic impact of chronic venous insufficiency: an underestimated public health problem. Int Angiol 1998; 17 (3): 161–7PubMed Van den Oever R, Hepp B, Debbaut B, et al. Socio-economic impact of chronic venous insufficiency: an underestimated public health problem. Int Angiol 1998; 17 (3): 161–7PubMed
2.
Zurück zum Zitat Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: S5–15PubMedCrossRef Fowkes FG, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: S5–15PubMedCrossRef
3.
Zurück zum Zitat Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology 2000; 51 (3): 197–205PubMedCrossRef Frick RW. Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon. Angiology 2000; 51 (3): 197–205PubMedCrossRef
4.
Zurück zum Zitat Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I–II): a randomized, double-blind, placebo-controlled trial. Arzneimittel Forschung 2000; 50 (2): 109–17PubMed Kiesewetter H, Koscielny J, Kalus U, et al. Efficacy of orally administered extract of red vine leaf AS 195 (folia vitis viniferae) in chronic venous insufficiency (stages I–II): a randomized, double-blind, placebo-controlled trial. Arzneimittel Forschung 2000; 50 (2): 109–17PubMed
5.
Zurück zum Zitat Antignani PL. Classification of chronic venous insufficiency: a review. Angiology 2001; 52 Suppl. 1: S17–26PubMedCrossRef Antignani PL. Classification of chronic venous insufficiency: a review. Angiology 2001; 52 Suppl. 1: S17–26PubMedCrossRef
6.
Zurück zum Zitat Doerschel K, Müller GJ. PC-integrated laser doppler blood flow measurements in skin In: Farkas DL, Leif RC, Priezzhev AV, et al., editors. Proceedings of the International Society for Optical Engineering (SPIE) 1996; 2678: 382–8 Doerschel K, Müller GJ. PC-integrated laser doppler blood flow measurements in skin In: Farkas DL, Leif RC, Priezzhev AV, et al., editors. Proceedings of the International Society for Optical Engineering (SPIE) 1996; 2678: 382–8
7.
Zurück zum Zitat Fagrell B. Advances in microcirculation network evaluation: an update. Int J Microcirc Clin Exp 1995; 15 Suppl. 1: S34–40CrossRef Fagrell B. Advances in microcirculation network evaluation: an update. Int J Microcirc Clin Exp 1995; 15 Suppl. 1: S34–40CrossRef
8.
Zurück zum Zitat Bollinger A, Jager K, Juenger M, et al. The vascular laboratory: advances in noninvasive techniques. World J Surg 1988; 12 (6): 724–31PubMedCrossRef Bollinger A, Jager K, Juenger M, et al. The vascular laboratory: advances in noninvasive techniques. World J Surg 1988; 12 (6): 724–31PubMedCrossRef
9.
Zurück zum Zitat Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347 (8997): 292–4PubMedCrossRef Diehm C, Trampisch HJ, Lange S, et al. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet 1996; 347 (8997): 292–4PubMedCrossRef
10.
Zurück zum Zitat Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res 1999; 36 Suppl. 1: S37–41CrossRef Struckmann JR. Clinical efficacy of micronized purified flavonoid fraction: an overview. J Vasc Res 1999; 36 Suppl. 1: S37–41CrossRef
11.
Zurück zum Zitat Ramelet AA. Clinical benefits of Daflon 500mg in the most severe stages of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: S49–56PubMedCrossRef Ramelet AA. Clinical benefits of Daflon 500mg in the most severe stages of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: S49–56PubMedCrossRef
12.
Zurück zum Zitat Bergan JJ, Schmid-Schoenbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500mg. Angiology 2001; 52 Suppl. 1: S43–7PubMedCrossRef Bergan JJ, Schmid-Schoenbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500mg. Angiology 2001; 52 Suppl. 1: S43–7PubMedCrossRef
13.
Zurück zum Zitat Signorelli SS, Malaponte MG, Di Pino L, et al. Venous stasis causes release of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha) by monocyte-macrophage. Clin Hemorheol Microcirc 2000; 22 (4): 311–6PubMed Signorelli SS, Malaponte MG, Di Pino L, et al. Venous stasis causes release of interleukin 1beta (IL-1beta), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNFalpha) by monocyte-macrophage. Clin Hemorheol Microcirc 2000; 22 (4): 311–6PubMed
14.
Zurück zum Zitat Coleridge Smith PD. Update on chronic-venous-insufficiency-induced inflammatory processes. Angiology 2001; 52 Suppl. 1: S35–42CrossRef Coleridge Smith PD. Update on chronic-venous-insufficiency-induced inflammatory processes. Angiology 2001; 52 Suppl. 1: S35–42CrossRef
15.
Zurück zum Zitat Schmid-Schoenbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: S27–34CrossRef Schmid-Schoenbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology 2001; 52 Suppl. 1: S27–34CrossRef
16.
Zurück zum Zitat Nees S, Weiss DR, Reichenbach-Klinke E, et al. Protective effects of flavonoids contained in the red vine leaf on venular endothelium against the attack of activated blood components in vitro. Arzneimittel Forschung 2003; 53 (5): 330–41PubMed Nees S, Weiss DR, Reichenbach-Klinke E, et al. Protective effects of flavonoids contained in the red vine leaf on venular endothelium against the attack of activated blood components in vitro. Arzneimittel Forschung 2003; 53 (5): 330–41PubMed
17.
Zurück zum Zitat Bollinger A, Leu AJ, Hoffmann U, et al. Microvascular changes in venous disease: an update. Angiology 1997; 48 (1): 27–32PubMedCrossRef Bollinger A, Leu AJ, Hoffmann U, et al. Microvascular changes in venous disease: an update. Angiology 1997; 48 (1): 27–32PubMedCrossRef
18.
Zurück zum Zitat Tulevski II, Ubbink DT, Jacobs MJ. Red and green laser Doppler compared with capillary microscopy to assess skin microcirculation in the feet of healthy subjects. Microvasc Res 1999; 58 (2): 83–8PubMedCrossRef Tulevski II, Ubbink DT, Jacobs MJ. Red and green laser Doppler compared with capillary microscopy to assess skin microcirculation in the feet of healthy subjects. Microvasc Res 1999; 58 (2): 83–8PubMedCrossRef
19.
Zurück zum Zitat Cesarone MR, De Sanctis MT, Incandela L, et al. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). Angiology 2001; 52 Suppl. 2: S3–7PubMed Cesarone MR, De Sanctis MT, Incandela L, et al. Methods of evaluation and quantification of microangiopathy in high perfusion microangiopathy (chronic venous insufficiency and diabetic microangiopathy). Angiology 2001; 52 Suppl. 2: S3–7PubMed
Metadaten
Titel
Improvement of Cutaneous Microcirculation and Oxygen Supply in Patients with Chronic Venous Insufficiency by Orally Administered Extract of Red Vine Leaves AS 195
A Randomised, Double-Blind, Placebo-Controlled, Crossover Study
verfasst von
Ulrich Kalus
Juergen Koscielny
Alexandre Grigorov
Eckhard Schaefer
Hubertus Peil
Holger Kiesewetter
Publikationsdatum
01.03.2004
Verlag
Springer International Publishing
Erschienen in
Drugs in R&D / Ausgabe 2/2004
Print ISSN: 1174-5886
Elektronische ISSN: 1179-6901
DOI
https://doi.org/10.2165/00126839-200405020-00001

Weitere Artikel der Ausgabe 2/2004

Drugs in R&D 2/2004 Zur Ausgabe

Adis R&D Profile

Natalizumab

Adis R&D Profile

Conivaptan

Adis R&D Profile

AE 941